CGD Policy Blogs
In June 2004, at Sea Island, the G8 endorsed the Global HIV Vaccine Enterprise. This is a mechanism, first proposed in June 2003, which aims to enhance coordination, information sharing and global collaboration amongst the world's HIV vaccine researchers in industrialized and developing countries in both private and public sectors.
Sebastian Mallaby writes in today's Washington Post (requires free registration) of the Bush administration's opportunity to find common ground with European allies on the issue of AIDS vaccine development.
The essence of an advance market commitment is that sponsors would guarantee that, if a suitable vaccine is developed, they will pay for it to be bought and used in developing countries.
The Aeras Global TB Vaccine Foundation and the David Geffen School of Medicine at UCLA today announced they have begun the first clinical trial of a live recombinant tuberculosis vaccine in the U.S.
An editorial in this week's Economist magazine says:
"Britain's promise to buy vaccines against HIV/AIDS and malaria for distribution in poor countries, which it hopes will provide the financial carrot necessary to get drug firms to develop them, is a potentially excellent use of an aid budget."
The Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM) was established very quickly in 2001 in response to a widespread perception that a rapid scale-up in financing was critical in the fight against the three diseases. Since it began operations in January 2002, GFATM has made important progress. It has raised substantial funding and become the world’s largest donor for TB and malaria. 70% of the programs reaching the two-year renewal stage are showing solid results. Rwanda, for example, has put over 4,000 people on ARV treatment, more than double its program target, and GFATM programs in aggregate have financed ARV treatment for 130,000 people to date.
Immunization is one of the safest ways to reduce disease and poverty in developing countries. But 3 million people die every year of vaccine-preventable diseases; and that will likely rise to 4.5 million when rotavirus and pneumococcus vaccines are available, if past experience is any guide. And progress towards vaccines suitable for HIV, malaria and tuberculosis is painfully slow.